Drugs / YHD1119
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05012436 | Jul 2021 → May 2022 | impaired renal function disease | Yuhan Corporation | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02985216 | Feb 2017 → Apr 2018 | neuropathy, painful | Yuhan Corporation | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YHD1119 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05012436 ↗ |
| Known as | pregabalin | “A new sustained-release (SR) pregabalin tablet, YHD1119, was formulated for once-daily dosing.” PMID 38197000 ↗ Dec 2023 |
| Known as | Y150T | “Eight subjects in Cohort A received a YHD1119 75 mg tablet (Y75T) and a YHD1119 150 mg tablet (Y150T) in each period, and eight subjects in Cohort B received a Y75T.” PMID 38197000 ↗ Dec 2023 |
| Known as | Y75T | “Eight subjects in Cohort A received a YHD1119 75 mg tablet (Y75T) and a YHD1119 150 mg tablet (Y150T) in each period, and eight subjects in Cohort B received a Y75T.” PMID 38197000 ↗ Dec 2023 |
| Route | Oral | “YHD1119 150mg, PO” NCT02985216 ↗ |